diseases

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – December 14,…

4 days ago

Latest Data of InnoCares Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

December 08, 2025 21:04 ET  | Source: InnoCare Pharma BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969;…

1 week ago

Servier’s Voranigo (vorasidenib) Receives Prix Galien Awards Across Multiple Regions

Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product…

1 week ago

Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease

December 05, 2025 21:00 ET  | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…

2 weeks ago

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the…

3 weeks ago

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 21, 2025 16:06 ET  | Source: Supernus Pharmaceuticals, Inc. ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,…

4 weeks ago

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

November 10, 2025 21:56 ET  | Source: Vor Biopharma BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq:…

1 month ago

Edesa Biotech Announces Upcoming Conference Schedule

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…

2 months ago

Total Investment of Approx. USD 11.6 Million in TB and NTD R&D Projects With Partners Including Fujifilm, Stop TB Partnership, and the Ohio State University

TOKYO, Oct. 29, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.73…

2 months ago

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

LEHI, Utah, Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes…

2 months ago